Skip to main content
MJHS
Navigation
Journal Navigation
Article Navigation
opened article
Volum 11, Issue 3
September 2024
Cover Image

Article contents

opened journal
Volum 11, Issue 3
September 2024
Cover Image

Abstract

Introduction

Autoimmune hemolytic anemia occurs due to the accelerated destruction of erythrocytes as a result of the dysfunction of immune system cells, which produce antibodies against the normal antigens of the membrane of hematopoietic cells. One of its causes is systemic lupus erythematosus.

Materials and methods

We present a case of a 20-year-old patient who was hospitalized with acute autoimmune hemolytic anemia, having been diagnosed with SLE at the age of 18 years. At the onset of the disease, hemolytic anemia was a differential diagnostic challenge.

Results

The differential diagnosis between primary and secondary autoimmune hemolytic anemia (AIHA) was an important step. The presence of antinuclear antibodies (ANA Hep2, Anti-dsDNA, Anti-cardiolipin, Anti-phospholipids, anti-Ro, Anti-Sm B) were important arguments in making the diagnosis. The relapse of AIHA was caused by inadequate treatment, due to a lack of compliance. Pulse therapy combined with methylprednisolone and cyclophosphamide successfully resolved the AIHA. 

Conclusions

Hematological abnormalities are commonly seen in SLE patients, but hemolytic autoimmune anemia is a rare condition. A timely diagnosis of the cause of hemolytic anemia and proper treatment of lupus by correcting autoimmune disorders are crucial in disease management. Pulse therapy combined with corticosteroids and immunosuppressants is effective in acute relapses of hemolytic anemia. 

Key Messages

What is not yet known on the issue addressed in the submitted manuscript

The submitted manuscript introduces a rare case of recurrence of acute autoimmune hemolytic anemia in a patient with systemic lupus erythematosus. The cause and triggers for this phenomenon are still unclear. 

The research hypothesis

The manuscript does not explicitly state a research hypothesis, as it primarily focuses on reporting a rare case of AIHA in the course of SLE.

The novelty added by manuscript to the already published scientific literature

This manuscript contributes to the existing scientific literature by presenting a novel case of a patient with SLE, who initially presented with autoimmune hemolytic anemia, posing a diagnostic challenge. Without adequate treatment, patients are at risk of relapse with adverse consequences.

Introduction

Systemic lupus erythematosus (SLE) is an autoimmune disease with an unclear etiology and complex pathogenesis. The immune response in SLE is directed against self-nuclear and non-nuclear nucleic acid-protein complexes [1]. Autoimmune hemolytic anemia (AIHA) is a rare autoimmune disease in which red blood cells are exposed to autoantibodies, which causes a significant decrease in their lifespan. AIHA may manifest in SLE patients at the time of diagnosis or within the first year of the disease [2]. Autoimmune hemolytic anemia manifests itself in approximately 5-10% of SLE patients [2, 3]. AIHA involves the presence of antibodies that react to heat, cold, or mixed types of reactive antibodies that are directed against antigens on the surface of red blood cells. Warm autoimmune hemolytic anemia (warm agglutinin disease) is usually manifested by asthenia and other constitutional symptoms and is diagnosed by the presence of IgG antibodies. About half of the cases of warm AIHA are recognized as secondary to the underlying disease. Warm AIHA in SLE is often associated with the presence of antiphospholipid antibodies and  with an increased risk of thrombosis [4, 5].

The essential treatment of AIHA is based on suppression of autoantibody production by monotherapy or combination therapy with glucocorticoids (GC) and/or rituximab and, more rarely, with immunosuppressants such as cyclophosphamide, azathioprine. Reducing the destruction of red blood cells by splenectomy is currently considered the third-line of treatment for warm AIHA [6, 7].

Here we report a rare case of SLE with autoimmune hemolytic anemia at the onset of the disease, with relapses due to inadequate treatment in a non-compliant patient.

Case report

We report the case of a 20-year-old man, hospitalized with complaints of general weakness, asthenia, dyspnea, fever, and icteric sclera. He has a 2-year history of SLE and treatment with low dose of methylprednisolone. The onset of the disease was marked by warm autoimmune hemolytic anemia. Laboratory results showed a low level of hemoglobin, erythrocytes and haptoglobin and a high level of indirect bilirubin and lactate dehydrogenase, reticulocytosis.

Material and methods

Complete blood count revealed macrocytic anemia with Hb 49 g/L, RBC 0.98x1012/L, with no changes in platelet and white blood cell count. At the biochemical examination, hyperbilirubinemia with increase of both direct and indirect bilirubin (total bilirubin 71.4 μmol/L, direct bilirubin 20.71 μmol/L and indirect bilirubin 50.69 μmol/L), hypertransaminasemia (ALT 219.8 U/L, AST 178.1 U/L), decreased serum haptoglobin (0.590 g/L) and increased lactate dehydrogenase (LDH 556.4 U/L) activity were observed. The diagnose of systemic lupus erythematosus was established in accordance with the 2019 EULAR/ACR  classification criteria for SLE [8-10].

Results

An 18-year-old male patient presented to the emergency unit with generalized weakness, dizziness, arthralgia, and abdominal pain. The symptoms appeared a week ago and were accompanied by a fever of 38-39°C. At the physical examination, the following were observed: pale skin, icteric sclera, local hyperemia on the fingers, ulceration in the area of the right big toe, skin peeling at the level of the fingers and toes, subacute skin rash and edema of the lower limbs. Auscultation of the lungs revealed rough vesicular breathing, dry murmurs bilaterally in basal area. The heart sounds were clear and rhythmic. Palpation of the abdomen caused pain in the epigastric region. The liver was enlarged (10 cm bellow the edge of the right rib). The spleen was enlarged to 10 cm in longitudinal diameter. Vital signs at admission: temperature 37.9°C, pulse 78 /min, BP 125/80 mmHg, RR 19 per minute and SpO2 99%. Due to severe anemia, the patient was hospitalized in the intensive care unit, where an erythrocyte mass transfusion was performed during the first 3 days (6 doses of erythrocyte concentrate). 

After the improvement of the hematological indices, the patient was transferred to the rheumatology department. Physical examination showed urticaria, local hyperemia in the hands, ulceration in the area of the right big toe, peeling of the skin in the fingers and toes, signs of pruritus in the lower extremities, photosensitivity, subacute skin rash. From the patient’s medical history, it was found that the patient was diagnosed with SLE with antiphospholipid syndrome accompanied by autoimmune hemolytic anemia 3 years ago. At the onset, he presented with general asthenia, vertigo, nausea, vomiting, asthenia and fever. As the hemoglobin level was very low (72 g/l), differential diagnostic measures were taken (sternal puncture with bone marrow investigation and immunological studies). The association of hemolytic anemia with positive antinuclear antibodies (ANA on Hep2 cells, anti-dsDNA antibodies, anti-cardiolipins, anti-phospholipids, anti-Ro, Anti-Sm-B in diagnostic titer and anti-histones, Anti-Mi-2β, anti-nucleosomes, anti-RNP, Anti-Ku, anticentromere in small titer), provided strong evidence for the diagnosis of SLE according to the 2019 EULAR/ACR classification criteria of systemic lupus erythematosus. Treatment with glucocorticosteroids was initiated with a dose of 60 mg/day of Prednisone equivalent, with dose tapering in outpatient settings after stabilization of the condition. The patient did not comply with the medical prescriptions, and rapidly reduced the dose of Methylprednisolone eventually discontinuing it completely. Upon discontinuation of treatment, symptoms of clinical exacerbation and signs of hemolytic anemia reappeared. 

During the last hospitalization, measures were taken to rule out digestive hemorrhage and assess the extent of internal organ damage. Fibrogastroduodenoscopy revealed catarrhal gastritis without signs of hemorrhage, and the abdominal ultrasound examination revealed hepatomegaly and splenomegaly. No obvious changes on transthoracic echocardiography. X-ray examination of the chest demonstrates interstitial lung involvement (Fig. 1).

Laboratory results are presented in Tables 1 and 2.

 

Table 1. Hematological parameters of patient during hospitalization

Parameter

Date 

Reference range

Units

15.03

16.03

17.03

18.03

19.03

22.03

Hemoglobin

49

61

76

92

102

100

130-170

g/L

Hematocrit

13.4

17

21

25

28.7

28.6

39-54

%

Red blood cells

0.89

1.31

1.7

2.1

2.49

2.54

4.0-6.0

*10^12/L

Platelets

205

155

118

126

160

238

150-450

*10^9/L

MCV

150.6

132.3

123.7

118.3

115.3

112.6

78-95

fL

MCH

55.1

46.9

45.0

43.2

41.0

39.4

27-36

pg

MCHC

36.6

35.5

36.4

36.5

35.5

35.0

32-36

g/dL

PDW

9.5

9.3

9.3

11.0

10.4

9.6

11-16.6

fL

MPV

10.0

9.9

9.7

10.1

10.0

9.5

7.4-11.0

fL

P-LCR

23.6

23.3

22.3

25.7

24.1

20.8

13-43

%

White blood cells

12.45

6.7

3.9

3.5

3.92

4.83

3.6-10.0

*10^9/L

Neutrophils

82.9

72

56

55

66.7

65.2

42.2-75.2

%

Eosinophils

0.2

0.6

2.1

3

3.6

0.0

0-4.0

%

Basophiles 

0.2

0.0

0.3

0.3

0.3

0.0

0-0.6

%

Monocytes 

6.3

8

10

11

7.7

11.6

2.2-8.0

%

Lymphocytes

10.4 

1.29

19 

1.29

31 

1.22

31 

1.07

21.7 

0.85

23.2 

1.12

20.5-45.0

1-4

%

*10^9/L)

ESR

 

27

26

24

6

5

 

mm/h

Reticulocytes

 

 

 

 

170.9

 

0.2-1.0

%

Morphology

Macrocytosis

 

 

 

Macrocytosis
Reticulocytosis
Anemia

Macrocytosis
Anisocytosis

 

 

Note: MCV - mean corpuscular volume; MCH - mean corpuscular hemoglobin; MCHC - mean corpuscular hemoglobin concentration; PDW - platelet distribution width; MPV - mean platelet volume; P-LCR - platelet-large cell ratio; ESR - erythrocyte sedimentation rate.

Table 2. Biochemical parameters of patient during hospitalization

Parameter

Date

Reference range

Units

15/03

16/03

17/03

18/03

22/03

Total bilirubin

71.4

54.4

39.2

33.9

14.57

2.0-21.0

μmol/L

Direct bilirubin

20.71

16.4

13.7

11.4

 

<5.13

μmol/L

Indirect bilirubin

50.69

38.0

25.5

22.5

 

<16.4

µmol/L

AST

178.1

123

68

37

12.7

<35

U/L

ALT

219.8

160

109

74

22.9

<45

U/L

Urea

9.27

8.3

6.5

5.7

7.70

2.8-7.2

mmol/L

Creatinine

134.3

106

72

58

47.9

70-115

μmol/L

Amylase

63.7

 

 

 

 

28-100

U/L

Albumin 

 

 

 

 

28.6

35-53

g/l

y-GT

 

 

 

 

34.0

11-50

U/L

LDH

 

 

 

 

556.4

240-480

U/L

CRP

 

 

 

 

2.7

<5

  mg/L

RF

 

 

 

 

6.0

0-15

IU/mL

Na

 

 

 

 

142.0

130-157

mmol/l

K

 

 

 

 

4.18

3.6-5.-

mmol/l

Haptoglobin

 

 

 

 

0.590

0.9-2.2 

g/L

Note: AST – aspartate aminotransferase; ALT- alanine aminotransferase; y-GT - gamma-glutamyl transpeptidase; LDH - lactate dehydrogenase; CRP – C-reactive protein; RF – rheumatoid factor; Na - sodium; K - potassium.

 

The physical examination revealed clinical signs characteristic of the evolution of systemic lupus erythematosus, such as acute photosensitive skin rash, necrotizing vasculitis in the fingers, scratching lesions and livedo reticularis (Fig. 2)

 

Fig 1. Chest X-ray with diffuse interstitial lung involvement most characteristic for lupus pneumonitis 

 

A

B

C

D

Fig 2. Skin manifestations observed in the patient

A, B - subacute skin rash, C - necrotizing digital vasculitis, D - scratching lesions

 

In the rheumatology department, high doses of glucocorticoids (Methylprednisolone 250 mg intravenously for 3 days as pulse therapy) were initiated, followed by prolonged treatment with Prednisolone 40 mg/day per os with dose adjustment depending on the effectiveness of the treatment measured by validated tools.

On the third day after the installation of the peripheral venous catheter (ulnar vein) pain, swelling and hyperemia in the area of the venipuncture appeared. The catheter was removed, and the vascular Doppler examination detected a non-occlusive thrombosis of the veins of the upper arm. Administration of Clexane at a dose of 2000 Un/day resolved this process.

As can be seen in the case presented by us, not all the elements of AIHA are manifest. Its peculiarities include anemia with macro- and anisocytosis, hyperbilirubinemia, hypohaptglobinemia and increased liver enzymes (AST, ALT, LDH), with an absence of thrombocytopenia. The presence of AIHA is associated with a more severe course of the disease, onset at a young age and multisystemic involvement (pulmonary, joint, vascular, thrombotic events). Non-compliance worsens the symptoms, futher endangering the patient's life.

Discussion

SLE is a systemic autoimmune disease in which tolerance to one's own antigens is lost. Autoantibodies cause cell and tissue destruction through cytotoxicity reactions or the formation of immune complexes. It can affect any organ, the initial symptoms are often non-specific, and the correct diagnosis is difficult. Women of childbearing age are more frequently affected, only approximately 10% of patients are men [1]. 

Autoimmune hemolytic anemia may be the first manifestation of systemic lupus erythematosus and can occur several years before the diagnosis of SLE is established. For differential diagnosis, the authors recommend the determination of SLE (specific antinuclear antibody) marker tests in the presence of symptoms characteristic of the disease, using the 2019 EULAR/ACR diagnostic criteria. Among these criteria is autoimmune hemolytic anemia (which contributes 4 points in favor of the diagnosis of SLE) [8-10]. Hemolytic anemia in patients with SLE is rare and is possibly caused by anti-erythrocyte or microangiopathic antibodies [2-5].

Autoimmune hemolytic anemia in patients with SLE can be the cause of various complications and multi-organ damage. The risk of ischemia and thrombotic events should not be overlooked, as the products of hemolysis are toxic to several cell types and tissues. Excess iron and hemoglobin can also affect the kidneys, especially in those with lupus nephritis.

González LA et al. in a Latin American cohort study (2023) on a group of 1364 patients with lupus, mentions that severe AIHA is observed in about 3.6% of patients, particularly at the onset of the disease. Male sex and high activity of the disease are risk factors for its development. The authors hypothesize that hematological manifestations in a patient with SLE could predict the occurrence of AIHA in the near future [11].

 Turk E. et al. (2024) in a large Nationwide Inpatient Sample (NIS), conclude that AIHA contributes to the increased mortality of patients with SLE due to acute myocardial infarction, cerebral stroke.They emphasize that AIHA must be promptly diagnosed in patients with lupus, considering it an unfavorable risk factor related to patient mortality  [6].

At present, there is no broad consensus on the treatment of SLE patients. It depends on the clinical manifestations and activity of the disease, damage to life-threatening organs (lungs, heart, kidneys, nervous system). Most authors consider the use of corticosteroids in patients with AIHA to be appropriate, with a gradual reduction of the dose once a stable clinical effect is achieved, in order to reach an adequate maintenance dose. The role of immunosuppressors in the treatment of AIHA is not well defined. Some authors show the efficacy of Rituximab in the treatment of patients with SLE and AIHA [7].

Conclusions

The particularities of this clinical case confirm the severity of the evolution of systemic lupus erythematosus in association with autoimmune hemolytic anemia. Intensive treatment with corticosteroids along with erythrocyte mass transfusions for the correction of anemia at the onset of this syndrome, as well as in cases of relapse, is effective in most instances. Once the desired effect is achieved, the dose of CS should be gradually reduced until an effective maintenance dose is reached. In refractory cases, it is necessary to consider the administration of immunosuppressors, such as Rituximab. Further research is needed to evaluate predictive factors, as well as to discover new drugs effective in patient management.

Competing interests

None declared.

Authors’ contribution

SP, SA devised the main conceptual ideas of the paper. VT, LD drafted the manuscript. LD, VT, VC collected the data from patient. All authors reviewed the manuscript and approved the final version. 

Informed consent for publication

Obtained.

Funding

None.

Authors’ ORCID IDs

Vera Tcaci – https://orcid.org/0009-0007-6435-7673

Serghei Popa – https://orcid.org/0000-0001-9348-4187

Svetlana Agachi – https://orcid.org/0000-0002-2569-7188

Lucia Dutca – https://orcid.org/0000-0002-1815-2294

Valeriu Corotaș – https://orcid.org/0009-0008-2552-4720

References

  1. Systemic lupus erythematosus. In: Groppa L, Popa S, Rotaru L, et al. Rheumatology and nephrology: Textbook. Chișinău: Lexon Prim; 2019. p. 98-120. ISBN 978-9975-3344-1-9.

  2. Domiciano DS, Shinjo SK. Autoimmune hemolytic anemia in systemic lupus erythematosus: association with thrombocytopenia. Clin Rheumatol. 2010 Dec;29(12):1427-31. doi: 10.1007/s10067-010-1479-2. 

  3. Lu Y, Huang XM. Autoimmune hemolytic anemia as an initial presentation in children with systemic lupus erythematosus: two case reports. J Int Med Res. 2022 Aug;50(8):3000605221115390. doi: 10.1177/03000605221115390. 

  4. Kokori SI, Ioannidis JP, Voulgarelis M, Tzioufas AG, Moutsopoulos HM. Autoimmune hemolytic anemia in patients with systemic lupus erythematosus. Am J Med. 2000;108(3):198-204. https://doi.org/10.1016/S0002-9343(99)00413-1.

  5. Gormezano NWS, Kern D, Pereira OL, et al. Autoimmune hemolytic anemia in systemic lupus erythematosus at diagnosis: differences between pediatric and adult patients. Lupus. 2017;26(4):426-430. doi: 10.1177/0961203316676379.

  6. Turk E, Deenadayalan V, Obeidat K, Rodriguez P. Outcomes of autoimmune hemolytic anemia in patients with systemic lupus erythematosus: a nationwide inpatient sample study [abstract]. Arthritis Rheumatol. 2022;74(Suppl 9) [cited 2024 Apr 12]. Available from: https://acrabstracts.org/abstract/outcomes-of-autoimmune-hemolytic-anem…

  7. Pavo-Blanco M, Novella-Navarro M, Cáliz-Cáliz R, Ferrer-González MA. Rituximab in refractory autoimmune hemolytic anemia in systemic lupus erythematosus. Reumatol Clin. 2018;14(4):248-249. doi: 10.1016/j.reumae.2017.07.007.

  8. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019 Sep;71(9):1400-1412. doi: 10.1002/art.40930.

  9. Ameer M, Chaudhry H, Mushtaq J, et al. An overview of systemic lupus erythematosus (SLE) pathogenesis, classification, and management. Cureus. 2022;14(10):e30330. doi: 10.7759/cureus.30330.

  10. Fanouriakis A, Tziolos N, Bertsias G, et al. Update in the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021;80:14-25. https://doi.org/10.1136/annrheumdis-2020-218272.

  11. González LA, Alarcón GS, Harvey GB, et al. Predictors of severe hemolytic anemia and its impact on major outcomes in systemic lupus erythematosus: data from a multiethnic Latin American cohort. Lupus. 2023;32(5):658-667. doi: 10.1177/09612033231163745.

 

More articles

Research Laparoscopic peritoneal lavage – a new treatment strategy in spontaneous bacterial peritonitis and liver cirrhosis
Gheorghe Anghelici1,2, Tatiana Zugrav1,2*, Sergiu Pisarenco1, Oleg Crudu2, Gheorghe Lupu2, Ana Apascaritei1
https://doi.org/10.52645/MJHS.2024.3.01
The laparoscopic approach in spontaneous bacterial peritonitis in patients with decompensated liver cirrhosis allows for better sanitation of the abdominal cavity, improves peritoneal absorption, and deserves establishment as clinical practice for patients with ascites and peritonitis and cirrhosis.
Research Childbirth at advanced reproductive age: the impact of biopsychosocial factors on the mode of delivery
Rodica Scutelnic1,2*, Larisa Spinei1
https://doi.org/10.52645/MJHS.2024.3.02
Advanced reproductive age has been associated with a higher risk of cesarean section compared to vaginal delivery. The influence of age is modulated by various sociodemographic, medical, and obstetric characteristics, including area of residence, education level, history of cesarean section, parity, pregnancy and delivery complications, pre-existing chronic conditions, antenatal care and provision of information on risk factors.
Research Deep endometriosis – impact on infertility, endometriosis fertility index, and reproductive prognosis (comparative study)
Nadejda Codreanu*, Elena Ivanova
https://doi.org/10.52645/MJHS.2024.3.03
EFI in patients with DIE does not reflect all aspects of infertility and has reservations, and consideration of both physical symptoms and sexual health is crucial in managing DIE to optimize fertility outcomes. These findings open the way to the feasibility of surgical treatment of DIE to improve sexual quality of life, which will reduce the need for IVF and increase the chances of spontaneous pregnancy in patients, but this conclusion requires further investigation in randomized clinical trials.
Research Postoperative urinary retention - prevalence and risk factors: prospective, cohort study
Natalia Belîi1,2*, Cătălina Lozan1
https://doi.org/10.52645/MJHS.2024.3.04
The prevalence of postoperative urinary retention in a single-center surgical population from the Republic of Moldova varies between 5.5% and 7.9%, depending on the criteria for postoperative urinary retention applied. This variation highlights the need for a consensus on diagnostic criteria for postoperative urinary retention is needed. Patients with hypertension and diabetes mellitus were more likely to develop postoperative urinary retention. Patients with pre-existing neurological disorders such as positive history for stroke and diabetic polyneuropathy were more susceptible for postoperative urinary retention.
Review Management of diabetic retinopathy in pregnancy
The risk of retinopathy development may increase during pregnancy. Serious effects can arise for both the mother and the fetus, even though retinopathy is not common during pregnancy. It is possible to avoid significant retinopathy by carefully planning a young diabetic woman's pregnancy and proceeding promptly to laser photocoagulate in cases of severe non-proliferative retinopathy. A tendency for regress is frequently seen in diabetic retinopathy during the post-natal period. Subsequent pregnancies do not significantly increase the risk of progression if the retinopathy is stable before pregnancy.